About Immunogenx
Immunogenx is a company based in Durham (United States) founded in 2013.. The company has 6 employees as of December 31, 2022. Immunogenx has completed 1 acquisition, including Alvine Pharma. Immunogenx offers products and services including Therapeutic Solution. Immunogenx operates in a competitive market with competitors including Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others.
- Headquarter Durham, United States
- Employees 6 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Immunogenx, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Latest Funding Round
$2.2 M (USD), Grant
Sep 08, 2020
- Investors
-
Employee Count
6
as on Dec 31, 2022
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Immunogenx
Immunogenx offers a comprehensive portfolio of products and services, including Therapeutic Solution. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops therapies to address gluten-free diet challenges for celiac disease patients.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Immunogenx
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $2.2M
-
First Round
First Round
(15 Sep 2017)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2020 | Amount | Grant - Immunogenx | Valuation |
investors |
|
| Sep, 2017 | Amount | Grant - Immunogenx | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Immunogenx
Immunogenx has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Immunogenx
Immunogenx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Alvine Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developing therapeutics for autoimmune and inflammatory diseases.
|
2005 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Immunogenx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Immunogenx Comparisons
Competitors of Immunogenx
Immunogenx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, UCB, Grifols, Kymeratx and PureTech Health, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for immunological and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Plasma-derived therapies are developed to treat multiple diseases.
|
|
| domain | founded_year | HQ Location |
Small molecule protein degraders are developed for various disorders.
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Immunogenx
Frequently Asked Questions about Immunogenx
When was Immunogenx founded?
Immunogenx was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Where is Immunogenx located?
Immunogenx is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
How many employees does Immunogenx have?
As of Dec 31, 2022, the latest employee count at Immunogenx is 6.
What does Immunogenx do?
Immunogenx develops solutions for the treatment and management of celiac disease. Its lead therapeutic candidate is a mixture of two gluten-specific recombinant proteases that helps in the degradation of gluten proteins in order to ameliorate the symptoms of celiac disease, when it was taken in conjunction with a gluten-free diet. It is currently in phase II clinical trials. Its lead diagnostic candidate CypCel is a metabolic assay. The patient is given a dose of the widely-used statin drug simvastatin, and the subsequent serum level of simvastatin is measured as a marker for the health of intestinal epithelium.
Who are the top competitors of Immunogenx?
Immunogenx's top competitors include ADMA Biologics, BioNTech and Generate Biomedicines.
What products or services does Immunogenx offer?
Immunogenx offers Therapeutic Solution.
How many acquisitions has Immunogenx made?
Immunogenx has made 1 acquisition, including Alvine Pharma.
Who are Immunogenx's investors?
Immunogenx has 1 investor. Key investors include HHS.